In 1998 a private-sector enterprise, Celera Genomics, headed by American biochemist and former NIH scientist J. Craig Venter, began to compete with and potentially undermine the publicly funded HGP. At the heart of the competition was the prospect of gaining control over potential patents on the...
which can differ both year to year and between ICs based on available funds; however, if an application is of particular relevance to the funding IC, it may still be awarded even if its score is above the typical percentile-based payline (i.e., the application receives...